Currently out of the existing stock ratings of Kevin Ellich, 27 are a BUY (50.94%), 22 are a HOLD (41.51%), 4 are a SELL (7.55%).

Kevin Ellich

Work Performance Price Targets & Ratings Chart

Analyst Kevin Ellich, carries an average stock price target met ratio of 95% that have a potential upside of 18.92% achieved within 357 days. Previously, Kevin Ellich worked at CRAIG HALLUM, PIPER SANDLER.

Kevin Ellich’s has documented 124 price targets and ratings displayed on 17 stocks. The coverage was on Healthcare, Financial Services, Industrials sectors.

Most recent stock forecast was given on AMED, Amedisys at 31-Oct-2019.

Wall Street Analyst Kevin Ellich

Analyst best performing recommendations are on NEOG (NEOGEN).
The best stock recommendation documented was for PETS (PETMED EXPRESS) at 10/17/2019. The price target of $20 was fulfilled within 4 days with a profit of $3.63 (22.17%) receiving and performance score of 55.44.

Average potential price target upside

of $22.34 (32.63%) on AME (AMETEK).
of $20.39 (16.08%) on LH (LABORATORY OF AMERICA HOLDINGS).
of $18.36 (22.28%) on DGX (QUEST DIAGNOSTICS).

AMED Amedisys PETS PetMed Express ZTS Zoetis HSIC Henry Schein LH Laboratory of America Holdings LHCG LHC Group NEOG Neogen TRUP Trupanion DGX Quest Diagnostics EHC Encompass Health Corp EXAS EXACT Sciences IDXX IDEXX Laboratories PDCO Patterson Companies ACHC Acadia Healthcare Company ADPT Adaptive Biotechnologies Corp AME Ametek DVA DaVita HealthCare Partners

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ben Hendrix (RBC)